Want to see NCEL full AI Analyst Report?
NCEL Stock Chart & Stats
$3.35
--
Market closed
$3.35
--
Day’s Range― - ―
52-Week Range$1.83 - $19.06
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.82K
Market Cap
$16.74M
Enterprise Value-$1.65T
Total Cash (Recent Filing)$710.00K
Total Debt (Recent Filing)$392.00K
Price to Earnings (P/E)8.9
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,383,871
10 Day Avg. Volume4,307
30 Day Avg. Volume5,819
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-98.83K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit71.95M
Enterprise Value/Ebitda589.34K
Forecast
1Y Price Target
$23.00Price Target Upside586.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe successful FDA Pre-IND meeting gives NewcelX clearer regulatory alignment for NCEL-101 and supports progression into IND-enabling work. This reduces uncertainty around the development path and may improve the company’s ability to secure resources and partnerships for clinical advancement.
Scientific LeadershipAdding a recognized specialist in islet transplantation and regenerative medicine strengthens the program’s scientific guidance as it moves toward clinical translation. His expertise may support trial design, credibility with stakeholders, and execution of the company’s beta-cell replacement strategy.
Low LeverageThe latest balance sheet shows limited debt relative to equity, reducing direct leverage pressure and interest-related constraints. Although losses create funding needs, the lightly levered structure gives NewcelX more flexibility to allocate capital toward development without carrying a large existing debt burden.
Bears Say
No Commercial RevenuePersistent zero revenue indicates that NewcelX has not yet reached commercial scale or established a recurring source of operating income. The business therefore remains dependent on successful development, regulatory progress, and external financing before it can support operations through internally generated sales.
Persistent Cash BurnContinually negative operating and free cash flow shows that the company consumes cash to maintain its current activities and cannot yet fund development internally. Continued burn increases reliance on equity or other financing, creating ongoing execution pressure and potential dilution for shareholders.
Worsening Interim FinancesThe first-half 2026 deterioration suggests that financial pressure remained significant after year-end 2025, with lower cash and equity alongside substantial losses. A shrinking liquidity cushion can constrain development spending and heighten the need for additional capital before key clinical milestones are reached.
NewcelX News
NCEL FAQ
What was NewcelX’s price range in the past 12 months?
NewcelX lowest stock price was $1.83 and its highest was $19.06 in the past 12 months.
What is NewcelX’s market cap?
NewcelX’s market cap is $16.74M.
When is NewcelX’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NewcelX’s earnings last quarter?
Currently, no data Available
Is NewcelX overvalued?
According to Wall Street analysts NewcelX’s price is currently Undervalued.
Does NewcelX pay dividends?
NewcelX does not currently pay dividends.
What is NewcelX’s EPS estimate?
NewcelX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NewcelX have?
NewcelX has 5,383,871 shares outstanding.
What happened to NewcelX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NewcelX?
Currently, no hedge funds are holding shares in NCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NewcelX
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
NCEL Stock 12 Month Forecast
Average Price Target
$23.00
▲(586.57% Upside)